Literature DB >> 6942711

Metabolic interactions between opiates and alcohol.

M J Kreek.   

Abstract

1. Acute preperfusion with ethanol does not alter significantly the initial hepatic extraction or subcellular distribution of narcotics, or the immediate biotransformation of the long-acting narcotic, methadone, using the isolated perfused rabbit liver. However, the acute administration of ethanol may alter distribution and/or impair hepatic drug metabolism in perfusion studies of longer duration, or in vivo, as has been suggested by others in studies of several drugs. 2. Following chronic treatment with both ethanol and methadone in the rat, plasma levels of unmetabolized methadone, determined by gas liquid chromatography, are significantly lowered. 3. Following chronic treatment with methadone alone, blood elimination rates of ethanol are accelerated to a greater extent than following chronic treatment with ethanol alone in the rat; following chronic treatment with both methadone and ethanol, rates of ethanol elimination are accelerated to a significantly more rapid rate than following treatment with either agent alone. 4. To date, clinical studies in patients on chronic steady-dose methadone maintenance treatment, without liver disease, polydrug abuse, or heavy use of ethanol, show no significant acute dispositional interactions between methadone and ethanol. 5. Clinical studies in patients on chronic steady-dose methadone maintenance treatment, without liver disease, polydrug abuse, or heavy use of ethanol, show no significant dispositional interactions between methadone and disulfiram (Antabuse) when the latter was given for one week for study purposes only. 6. Clinical studies of possible dispositional interactions between methadone and ethanol in methadone-maintained patients, who are also chronic abusers of alcohol, are now in progress.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6942711     DOI: 10.1111/j.1749-6632.1981.tb12789.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  8 in total

1.  [Not Available].

Authors:  J Jage
Journal:  Schmerz       Date:  1989-09       Impact factor: 1.107

Review 2.  Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence.

Authors:  Chin B Eap; Thierry Buclin; Pierre Baumann
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

3.  Steady-state pharmacokinetics of methadone in opioid addicts.

Authors:  K Wolff; A W Hay; D Raistrick; R Calvert
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 4.  Opioid receptors: some perspectives from early studies of their role in normal physiology, stress responsivity, and in specific addictive diseases.

Authors:  M J Kreek
Journal:  Neurochem Res       Date:  1996-11       Impact factor: 3.996

Review 5.  Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review.

Authors:  Elinore F McCance-Katz; Lynn E Sullivan; Srikanth Nallani
Journal:  Am J Addict       Date:  2010 Jan-Feb

Review 6.  Alcohol use in opioid agonist treatment.

Authors:  Seonaid Nolan; Jan Klimas; Evan Wood
Journal:  Addict Sci Clin Pract       Date:  2016-12-08

Review 7.  Practical considerations for the clinical use of buprenorphine.

Authors:  Hendree E Jones
Journal:  Sci Pract Perspect       Date:  2004-08

8.  Problem alcohol use among problem drug users in primary care: a qualitative study of what patients think about screening and treatment.

Authors:  Catherine Anne Field; Jan Klimas; Joseph Barry; Gerard Bury; Eamon Keenan; Bobby P Smyth; Walter Cullen
Journal:  BMC Fam Pract       Date:  2013-07-13       Impact factor: 2.497

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.